Zuriaga María A, Fuster José J
Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain.
Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain; CIBER en Enfermedades Cardiovasculares (CIBER-CV), Madrid, Spain.
Clin Investig Arterioscler. 2023 Jan-Feb;35(1):35-41. doi: 10.1016/j.arteri.2021.09.006. Epub 2021 Dec 5.
Despite current standards of care, a considerable risk of atherosclerotic cardiovascular disease remains in both primary and secondary prevention. In this setting, clonal hematopoiesis driven by somatic mutations has recently emerged as a relatively common, potent and independent risk factor for atherosclerotic cardiovascular disease and other cardiovascular conditions. Experimental studies in mice suggest that mutations in TET2 and JAK2, which are among the most common in clonal hematopoiesis, increase inflammation and are causally connected to accelerated atherosclerosis development, which may explain the link between clonal hematopoiesis and increased cardiovascular risk. In this review, we provide an overview of our current understanding of this emerging cardiovascular risk factor.
尽管有当前的治疗标准，但在一级和二级预防中，动脉粥样硬化性心血管疾病仍存在相当大的风险。在这种情况下，由体细胞突变驱动的克隆性造血最近已成为动脉粥样硬化性心血管疾病和其他心血管疾病相对常见、强大且独立的风险因素。小鼠实验研究表明，TET2和JAK2突变是克隆性造血中最常见的突变，会增加炎症，并与动脉粥样硬化加速发展存在因果关系，这可能解释了克隆性造血与心血管风险增加之间的联系。在这篇综述中，我们概述了目前对这一新兴心血管风险因素的理解。
